News: Dosing Underway in World's First in Vivo CRISPR Trial for Primary Hyperoxaluria

YolTech Therapeutics dosed first two patients in YOLT-203 trial, an in vivo gene-editing therapy for primary hyperoxaluria type 1 (PH1), targeting AGXT gene mutations to reduce oxalate levels.